Stockscreener 앱 받기
173.33
1.72%
3.17
Abbvie Inc 주식(ABBV)의 최신 뉴스
Cantor initiates coverage of U.S. large-cap pharma stocks: Gilead, AbbVie at Buy - Baystreet.ca
Do Options Traders Know Something About AbbVie (ABBV) Stock We Don't? - Yahoo Finance
This American Water Works Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
AbbVie (ABBV) Initiated at Overweight by Cantor Fitzgerald with $210 Price Target | ABBV Stock News - GuruFocus
AbbVie price target lowered to $200 from $223 at BofA - TipRanks
Lobbying Update: $2,110,000 of ABBVIE INC. lobbying was just disclosed - Nasdaq
AbbVie (ABBV) Stock Moves -1.64%: What You Should Know - Yahoo Finance
Jim Cramer Is Bullish on AbbVie Inc. (ABBV) Ahead of Earnings - Insider Monkey
BofA Adjusts AbbVie (ABBV) Price Target Ahead of Q1 Results | ABBV Stock News - GuruFocus
Immunology Drugs Market Top Companies Study- Eli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer. - openPR.com
The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com
Is AbbVie Stock a Buy? - MSN
Lobbying Update: $50,000 of ABBVIE INC. lobbying was just disclosed - Nasdaq
Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
CERE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cerevel Therapeutics Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TradingView
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before June 3, 2025 to Discuss Your Rights – ABBV - TradingView
Is AbbVie Inc. (ABBV) the Best Large-Cap Value Stock to Buy as the Recession Hits? - Insider Monkey
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
AbbVie Inc. (NYSE:ABBV) Shares Sold by Canada Pension Plan Investment Board - MarketBeat
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - marketscreener.com
Atopic Dermatitis Drugs Market Forecast 2025-2034 | Rising Drug Approvals and Clinical Trial Successes Propel Revenue Growth, Making Atopic Dermatitis a High-Growth Market - GlobeNewswire Inc.
AbbVie (ABBV): A Top Dividend Monarch with Strong Growth Prospects - GuruFocus
Applications now open for Abbvie’s cystic fibrosis scholarship program - Cystic Fibrosis News Today
AbbVie (ABBV) Gets a Buy from Guggenheim - The Globe and Mail
Fund Update: Bank Pictet & Cie (Europe) AG added 78,930 shares of ABBVIE ($ABBV) to their portfolio - Nasdaq
AbbVie Inc. (ABBV): Among the Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
ABBV LAWSUIT ALERT: The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
AbbVie Inc. (ABBV) Stock Forecasts - Yahoo Finance
10 Innovative Healthcare Stocks to Watch in 2025 - Insider Monkey
AbbVie Inc. (ABBV): One of the Best Dividend Monarchs to Invest in Now - Insider Monkey
Interleukin Inhibitors Market Is Booming Worldwide | AbbVie - openPR.com
Drug company files suit against South Dakota over new 340B law - South Dakota Public Broadcasting
Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks - Yahoo Finance
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment - Yahoo Finance
Top Research Reports for AbbVie, TJX & Charles Schwab - MSN
AbbVie Asks Court to Extend Venclexta Cancer-Drug Patent’s Life - Bloomberg Law News
AbbVie Options Trading: A Deep Dive into Market Sentiment - Nasdaq
AbbVie Inc. (ABBV): One of the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Drugmaker sues SD over law preserving broad access to discounts for hospitals, pharmacies - Argus Leader
The Zacks Analyst Blog Merck and AbbVie - Yahoo Finance
10 Best Pharma Stocks to Buy for Long Term Growth - Insider Monkey
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie and Sandoz agree to drop court spat over Rinvoq patents - Endpoints News
ABBV vs. MRK: Which Drug Giant is a Better Buy Now? - Yahoo Finance
Arthralgia Market to Reach New Heights in Growth by 2032, - openPR.com
The Zacks Analyst Blog Merck And AbbVie - Barchart.com
Meta, TJX, Taiwan Semiconductor Manufacturing And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Earnings Preview: What to Expect From AbbVie's Report - Nasdaq
Earnings Preview: What To Expect From AbbVie's Report - Barchart.com
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Yahoo Finance
10 High Growth Forever Dividend Stocks To Invest In - Insider Monkey
Is AbbVie Inc. (ABBV) the Best Stock for 15 Years? - Insider Monkey
Skin Boosters Market to Witness Stunning Growth with AbbVie, Medytox, ExoCoBio - openPR.com
1.49%
0.14%
자본화:
|
볼륨(24시간):